Navigation Links
Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Date:6/5/2010

SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).  Dr. Tudor Eliade Ciuleanu, M.D., Ph.D., of Institute of Oncology, Cluj-Napoca, Romania and an investigator for the SPEAR trial, presented the data during an oral session at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago, IL.

"Results from this important study show that picoplatin is an active compound, with a demonstrated survival benefit among patients where the use of post-study chemotherapy between treatment arms was balanced," stated Dr. Ciuleanu.  "These data include a number of significant outcomes, including improved overall survival among those individuals who did not receive post-study chemotherapy, the study's principal confounding factor, and among early relapsing or platinum refractory patients, a clinically meaningful population.  Further, picoplatin exhibits a manageable safety profile consistent with prior clinical experience. These results warrant further investigation in this indication."

"The SPEAR trial provides valuable insight into picoplatin's potential as an effective new treatment option for the vastly underserved early relapsing or platinum refractory SCLC patient population," said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals.  "These results are encourag
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces $6.3 Million Financing
2. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
3. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
4. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
7. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
11. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)...  BioScrip ® , Inc. (NASDAQ: BIOS ) announced ... Officer, will present at the Bank of America Merrill Lynch 2014 ... Date: , , , Wednesday, December 3, 2014 , , ... , , , Location: , , , Boca Raton Resort and ... BioScrip, Inc. is a leading national provider ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, Inc., ... novel therapies for infectious diseases, announced today the ... internationally recognized key opinion leader in the areas ... advisory board. Founder and Chief Executive ... believe Dr. Opal,s extensive experience investigating bacterial toxins ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... According to the American,Academy of Dermatology (AAD), ... an inflamed skin condition characterized by red, scaly,and ... which tend to,flare up in the winter months, ... Eczema Care Moisturizing Cream and Body Wash, formulated,with ...
... Infection Control, WASHINGTON, Jan. 10 To ... minimize risks during times,of health crisis, DuPont (NYSE: ... its,healthcare products, DuPont(TM) Corian(R) solid surface, has been ... department. The product,recently was incorporated into a children,s ...
Cached Medicine Technology:New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... safe and produces an immune system response that could protect ... results reported by the U.S. National Institutes of Health. ... vaccine paves the way for field-testing it in the Ebola-stricken ... as January, said Dr. Anthony Fauci, director of the NIH,s ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... 2014 Dr. Ronald Receveur, who has a ... few oral health tips before patients dig into the annual ... New Albany affordable cosmetic dentistry, and his staff ... and sugar. While the staff wishes everyone a happy and ... how patients can enjoy a feast that is also healthy ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4
... The acquisition of Baptist Memorial Hospital in Forrest City, ... Systems. The acute health care centre which is 118-bedded ... Ark.). // ,In addition, some other assets would ... care center (Memphis-based Baptist Memorial Health Care Corp.) The ...
... new online application system for junior doctor posts is not ... the job prospects of many top students. This was the ... system being followed is the “Modernising Medical Careers system” which ... answers. ,The reason for this attack as claimed ...
... Scientists at the U.S. Department of Energy’s Brookhaven ... identifying the many species of microorganisms. They have ... of Applied Environmental Microbiology. Microbiology has many applications ... species useful for cleaning up contamination, to identify ...
... and weight loss failure turned to an online competition to ... a 4 month period.//, ,The competition hosted on WeightLossWars.com ... 25 miles, with the winner of the competition losing 9% ... Jen sending out invitations through WeightLossWars.com to her family and ...
... in matters of sleep till late the reason being ... ray of new light comes the IST project 'Sensation' ... different // countries, addressing sensing of physiological parameters, core ... a multipurpose sensing platform consisting of 17 micro sensors ...
... the protective clothing to astronauts going to space and ... the basis to design// protective clothing for fire fighters ... heat and dangerous circumstances. ,This project nicknamed ... that encompasses an inbuilt cooling system, with a technology ...
Cached Medicine News:Health News:Online recruitment criticised by doctors 2Health News:The Novel Cut and Splice Method Is Used To Recognize Different Microbes 2Health News:Sleep Science awakens from deep slumber! 2
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
Medicine Products: